Oversubscribed Rights Offering Generated $6.25 Million in Aggregate Gross Proceeds Offering Proceeds Satisfies Debt Covenant, ...

Corporation announced that the Company closed the subscription period of its previously announced rights offering at 5:00 PM ...

Cytosorbents ( (CTSO) ) has shared an update. CytoSorbents Corporation successfully closed an oversubscribed rights offering, raising $6.25 million in aggregate gross proceeds, which satisfies a debt ...

D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $8.71, a high ...

13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood ...

Fourth quarter product revenue is estimated to be in the range of $9M to $9.2M, representing 22% to 25% growth versus $7.35 million in the ...

This was corrected on 01/05/2025 at 1:03 AM. The revised post deletes Q4 and FY24 product revenue consensus ...

D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Presbia has higher earnings, but lower revenue than Cytosorbents. Presbia has a beta of 5.91 ...

23, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO) announces the commencement of its Rights Offering, previously detailed in our December 9, 2024 announcement press release.